Vaibhav Sahai
About
Vaibhav Sahai is a scholar working on Oncology, Surgery and Molecular Biology.
According to data from OpenAlex, Vaibhav Sahai has authored 145 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 52 papers in Surgery and 41 papers in Molecular Biology. Recurrent topics in Vaibhav Sahai's work include Pancreatic and Hepatic Oncology Research (67 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (46 papers) and Cancer Genomics and Diagnostics (26 papers). Vaibhav Sahai is often cited by papers focused on Pancreatic and Hepatic Oncology Research (67 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (46 papers) and Cancer Genomics and Diagnostics (26 papers). Vaibhav Sahai collaborates with scholars based in United States, France and South Korea. Vaibhav Sahai's co-authors include Sanjay Kakar, Mark M. Zalupski, Eric Van Cutsem, Do‐Youn Oh, Mitesh J. Borad, Antoine Hollebecque, Andrew Scott Paulson, Hui‐Ling Zhen, Gina M. Vaccaro and Hidayatullah G. Munshi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.
In The Last Decade
Vaibhav Sahai
137 papers receiving 4.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Vaibhav Sahai United States | 34 | 3.0k | 1.6k | 1.5k | 1.2k | 931 | 145 | 4.8k | ||
| Davide Melisi Italy | 42 | 3.5k 1.1× | 2.4k 1.5× | 1.6k 1.1× | 1.4k 1.2× | 1.3k 1.4× | 164 | 5.9k | ||
| Miao‐Zhen Qiu China | 38 | 2.5k 0.8× | 1.6k 1.0× | 1.1k 0.7× | 1.3k 1.0× | 1.6k 1.7× | 165 | 4.9k | ||
| Andrew H. Ko United States | 35 | 3.8k 1.2× | 1.4k 0.9× | 769 0.5× | 1.7k 1.4× | 963 1.0× | 150 | 4.9k | ||
| Shubham Pant United States | 32 | 2.7k 0.9× | 1.5k 0.9× | 753 0.5× | 1.2k 1.0× | 956 1.0× | 279 | 4.5k | ||
| Amit Mahipal United States | 34 | 2.6k 0.8× | 1.3k 0.8× | 1.6k 1.1× | 781 0.6× | 1.1k 1.2× | 266 | 4.4k | ||
| P. Murawa Poland | 16 | 3.0k 1.0× | 890 0.5× | 770 0.5× | 1.1k 0.9× | 1.2k 1.2× | 47 | 4.1k | ||
| Arndt Hartmann Germany | 38 | 1.7k 0.6× | 2.2k 1.3× | 1.2k 0.8× | 958 0.8× | 915 1.0× | 155 | 4.8k | ||
| Michael J. Pishvaian United States | 40 | 3.8k 1.2× | 1.9k 1.2× | 747 0.5× | 1.5k 1.2× | 1.1k 1.2× | 216 | 5.8k | ||
| Gerald W. Prager Austria | 32 | 1.7k 0.6× | 1.0k 0.6× | 783 0.5× | 921 0.8× | 802 0.9× | 171 | 3.5k | ||
| Marko Kornmann Germany | 39 | 2.4k 0.8× | 2.5k 1.5× | 697 0.5× | 1.7k 1.4× | 747 0.8× | 137 | 4.9k |
Countries citing papers authored by Vaibhav Sahai
Since
Specialization
Citations
This map shows the geographic impact of Vaibhav Sahai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vaibhav Sahai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vaibhav Sahai more than expected).
Fields of papers citing papers by Vaibhav Sahai
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vaibhav Sahai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vaibhav Sahai. The network helps show where Vaibhav Sahai may publish in the future.
Co-authorship network of co-authors of Vaibhav Sahai
This figure shows the co-authorship network connecting the top 25 collaborators of Vaibhav Sahai. A scholar is included among the top collaborators of Vaibhav Sahai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vaibhav Sahai. Vaibhav Sahai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bray, Alexander & Vaibhav Sahai. (2025). IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies. Current Oncology. 32(1). 44–44.
2.
King, Sarah, et al.. (2025). The Use of dSTORM-Based Single Exosome Analysis To Study Tetraspanin Abundance in Extracellular Vesicles. ACS Omega. 10(31). 34659–34665.
3.
Ebben, J., Jens C. Eickhoff, Dustin A. Deming, et al.. (2024). QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.. Journal of Clinical Oncology. 42(16_suppl). TPS4195–TPS4195.
4.
Sahai, Vaibhav, Kent A. Griffith, David B. Zhen, et al.. (2024). Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).. Journal of Clinical Oncology. 42(16_suppl). 4116–4116.
5.
Kelley, Robin Kate, James M. Cleary, Vaibhav Sahai, et al.. (2024). A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4197–TPS4197.
6.
Enzler, Thomas, Anna Nguyen, Jamal Misleh, et al.. (2024). A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. European Journal of Cancer. 201. 113950–113950.
7.
Jiang, Long, Weiwei Wang, Amanda K. Huber, et al.. (2024). Potentiating the radiation-induced type I interferon anti-tumoral immune response by ATM inhibition in pancreatic cancer. JCI Insight. 9(6).
8.
Enzler, Thomas, Jiaqi Shi, Brian D. Griffith, et al.. (2024). A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. International Journal of Molecular Sciences. 25(5). 2953–2953.
9.
Hadley, Scott, Vaibhav Sahai, Filip Bednar, et al.. (2023). Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer. Advances in Radiation Oncology. 8(6). 101266–101266.
10.
Pasternak, Amy L., Oxana Crysler, Paul Swiecicki, et al.. (2023). Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository. Clinical Pharmacology & Therapeutics. 114(2). 356–361.
11.
Gunchick, Valerie, et al.. (2023). Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy. The Oncologist. 28(6). 531–541.
12.
Griffith, Kent A., David B. Zhen, Chandan Kumar‐Sinha, et al.. (2023). Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04). Clinical Cancer Research. 29(13). 2394–2400.
13.
Pasternak, Amy L., et al.. (2023). Risk of Toxicity From Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles. Clinical Pharmacology & Therapeutics. 115(3). 452–456.
14.
Picozzi, Vincent J., Vaibhav Sahai, Diane M. Simeone, et al.. (2017). A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer. Annals of Oncology. 28. iii81–iii82.
15.
Waghray, Meghna, Malica Yalamanchili, Michele Dziubinski, et al.. (2016). GM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer. Cancer Discovery. 6(8). 886–899.
16.
Sahai, Vaibhav, Krishan Kumar, Lawrence M. Knab, et al.. (2014). BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen. Molecular Cancer Therapeutics. 13(7). 1907–1917.
17.
Knab, Lawrence M., Kazumi Ebine, Christina R. Chow, et al.. (2014). Snail Cooperates with KrasG12D In Vivo to Increase Stem Cell Factor and Enhance Mast Cell Infiltration. Molecular Cancer Research. 12(10). 1440–1448.
18.
Kim, Edward, Vaibhav Sahai, Ethan V. Abel, et al.. (2014). Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clinical Cancer Research. 20(23). 5937–5945.
19.
Kumar, Rajesh, et al.. (2000). Genetic diversity in mutant lines of Indian mustard (Brassica juncea).. 10(1). 1–4.
20.
Sarán, S., et al.. (1996). Landraces of rice (Oryza sativa L.) in Bihar. Indian Journal of Plant Genetic Resources. 9(1). 63–72.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Davide Melisi Breakdown of academic impact, for papers by Miao‐Zhen Qiu Breakdown of academic impact, for papers by Andrew H. Ko Breakdown of academic impact, for papers by Shubham Pant Breakdown of academic impact, for papers by Amit Mahipal Breakdown of academic impact, for papers by P. Murawa Breakdown of academic impact, for papers by Arndt Hartmann Breakdown of academic impact, for papers by Michael J. Pishvaian Breakdown of academic impact, for papers by Gerald W. Prager Breakdown of academic impact, for papers by Marko Kornmann